Daniel El Fassi
Daniel El Fassi
Department of Hematology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark
Patvirtintas el. paštas
B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study
D El Fassi, CH Nielsen, SJ Bonnema, HC Hasselbalch, L Hegedus
The Journal of Clinical Endocrinology & Metabolism 92 (5), 1769-1772, 2007
Ulcerative colitis following B lymphocyte depletion with rituximab in a patient with Graves’ disease
D El Fassi, CH Nielsen, J Kjeldsen, O Clemmensen, L Hegedüs
Gut 57 (5), 714-715, 2008
Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion
DE Fassi, CH Nielsen, HC Hasselbalch, L Hegedüs
Thyroid 16 (7), 709-710, 2006
Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies
D El Fassi, JP Banga, JA Gilbert, C Padoa, L Hegedüs, CH Nielsen
Clinical Immunology 130 (3), 252-258, 2009
The rationale for B lymphocyte depletion in Graves’ disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option
D El Fassi, CH Nielsen, HC Hasselbalch, L Hegedüs
European journal of endocrinology 154 (5), 623-632, 2006
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study
AL Sørensen, SU Mikkelsen, TA Knudsen, ME Bjørn, CL Andersen, ...
haematologica 105 (9), 2262, 2020
B-cell depletion with rituximab in the treatment of autoimmune diseases: Graves' ophthalmopathy the latest addition to an expanding family
CH Nielsen, DE Fassi, HC Hasselbalch, K Bendtzen, L Hegedüs
Expert opinion on biological therapy 7 (7), 1061-1078, 2007
Safety and efficacy of combination therapy of interferon‐α2 and ruxolitinib in polycythemia vera and myelofibrosis
SU Mikkelsen, L Kjær, ME Bjørn, TA Knudsen, AL Sørensen, ...
Cancer Medicine 7 (8), 3571-3581, 2018
Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease
D El Fassi, O Clemmensen, CH Nielsen, RZ Silkiss, L Hegedus
The Journal of Clinical Endocrinology & Metabolism 92 (10), 3762-3763, 2007
A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2
AL Tølbøll Sørensen, M Rolland, J Hartmann, ZB Harboe, C Roed, ...
Blood advances 5 (12), 2569-2574, 2021
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
S Verstovsek, AT Gerds, AM Vannucchi, HK Al-Ali, D Lavie, ...
The Lancet 401 (10373), 269-280, 2023
Systemic adverse events following rituximab therapy in patients with Graves’ disease
D El Fassi, CH Nielsen, P Junker, HC Hasselbalch, L Hegedüs
Journal of endocrinological investigation 34, e163-e167, 2011
Therapeutic cancer vaccination with a peptide derived from the calreticulin exon 9 mutations induces strong cellular immune responses in patients with CALR-mutant chronic …
J Handlos Grauslund, MO Holmström, NG Jørgensen, U Klausen, ...
Frontiers in Oncology 11, 637420, 2021
Genomic profiling of a randomized trial of interferon-α vs hydroxyurea in MPN reveals mutation-specific responses
TA Knudsen, V Skov, K Stevenson, L Werner, W Duke, C Laurore, ...
Blood advances 6 (7), 2107-2119, 2022
Application of new therapies in Graves' disease and thyroid-associated ophthalmopathy: animal models and translation to human clinical trials
JP Banga, CH Nielsen, JA Gilbert, D El Fassi, L Hegedus
Thyroid 18 (9), 973-981, 2008
Safety and efficacy of combination therapy of interferon-alpha2+ JAK1-2 inhibitor in the Philadelphia-negative chronic myeloproliferative neoplasms. Preliminary results from …
SU Mikkelsen, L Kjær, V Skov, ME Bjørn, CL Andersen, OW Bjerrum, ...
Blood 126 (23), 824, 2015
Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy
JF Nielsen, D El Fassi, CH Nielsen, L Hegedüs, SA Lauer, RZ Silkiss, ...
Acta Ophthalmologica 87 (8), 927-929, 2009
Long-term efficacy and safety of recombinant interferon alpha-2 vs. hydroxyurea in polycythemia vera: preliminary results from the three-year analysis of the daliah trial-a …
TA Knudsen, DL Hansen, LF Ocias, OW Bjerrum, M Brabrand, D El Fassi, ...
Blood 132, 580, 2018
Anti-CD20 antibody therapy for B-cell lymphomas.
RP Taylor, MA Lindorfer, CS Zent
The New England journal of medicine 367 (9), 876-7; author reply 878, 2012
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
C Fuchs Andersen, M Omar, A Glenthøj, D El Fassi, HJ Møller, ...
European Journal of Heart Failure 25 (2), 226-234, 2023
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20